Jounce Therapeutics, Inc. (JNCE)
(Delayed Data from NSDQ)
$5.79 USD
+0.42 (7.82%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.78 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[JNCE]
Reports for Purchase
Showing records 1 - 20 ( 86 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Eyes on INNATE Phase 2 Update in 1H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Multiple Upcoming Pipeline Updates; Adjusting PT to $11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
1Q2022 Update - Two Critical Catalysts in 2H2022 - Pullback Overdone, Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
INNATE Achieved Early Milestones; Catalyst-Rich 2H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
4Q2021 Update - Two Key Clinical PoC Data Readouts Reaffirmed for 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Industry: Medical - Drugs
INNATE Advancing Into Expansion Cohort Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q21 Update - A Solid Immuno-Oncology Play With Key Data Readouts in 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Industry: Medical - Drugs
Enrollment in INNATE Expansion Cohorts Imminent; JTX-1811 IND Cleared; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
2Q21 Update - Clinical Programs Accelerating With A Key Focus on JTX-8064
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z